Omalizumab to Treat Hyper-IgE (Job's) Syndrome

Clinical trial NCT00260702 · COMPLETED

Trial details

NCT number: NCT00260702
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Hyper-IgE Syndrome Job's Syndrome

Start date: 2005-11-24
Primary completion: 2010-03-19
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.